Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on VolitionRX, retaining the price target of $1.50.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen has given his Buy rating due to a combination of factors related to VolitionRX’s recent developments and strategic advancements. The inclusion of the Nu.Q NETs H3.1 assay in France’s DETECSEPS project marks a significant milestone for the company. This project, funded by the French government, aims to revolutionize the early detection of sepsis, and VolitionRX’s biomarker is central to this initiative. The assay’s ability to accurately distinguish sepsis from non-infectious systemic inflammation and its strong prognostic utility enhance its potential for broader adoption.
Additionally, VolitionRX has made strides in the cancer diagnostics field with the first sale of its Nu.Q Cancer assays to a leading cancer center in France. This sale is a step towards routine clinical use, potentially improving cancer management by providing valuable insights into patient outcomes. The company’s valuation, supported by a discounted cash flow analysis, suggests a promising future, although risks such as clinical development failures and market traction challenges remain. Overall, these developments underpin Yi Chen’s positive outlook and Buy rating for VolitionRX.